Core Viewpoint - Vista Energy, S.A.B. de C.V. (VIST) shows potential for significant upside, with a mean price target of $70.09 indicating a 44.4% increase from its current price of $48.53 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $12.72, indicating variability among analysts [2] - The lowest estimate is $50.00, suggesting a 3% increase, while the highest estimate is $90.00, indicating an 85.5% potential surge [2] - A low standard deviation signifies strong agreement among analysts regarding price movement direction [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about VIST's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 37% rise in the Zacks Consensus Estimate [12] - VIST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements [7][10] - Analysts may set overly optimistic targets due to business incentives, which can inflate price expectations [8]

Core Insights - HealthEquity (HQY) is projected to announce quarterly earnings of $0.90 per share, reflecting a year-over-year increase of 15.4% [1] - Revenue is expected to reach $319.96 million, marking a 6.5% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' projections [1] Revenue Estimates - 'Revenue- Service' is estimated at $119.50 million, showing a year-over-year change of +0.3% [4] - 'Revenue- Custodial' is projected to be $156.61 million, indicating an increase of +11.1% from the previous year [4] - 'Revenue- Interchange' is expected to reach $42.88 million, reflecting a +6.4% change year over year [4] Asset and Account Estimates - 'Total HSA Assets' are estimated at $33.68 billion, up from $29.99 billion a year ago [5] - 'Total HSA investments' are projected at $16.22 billion, compared to $13.60 billion in the same quarter last year [5] - 'CDBs Accounts' are forecasted to reach 7.05 million, slightly up from 6.96 million in the previous year [5] Additional Metrics - 'Total Accounts' are expected to reach 17.26 million, compared to 16.46 million in the same quarter last year [6] - 'Total HSA cash' is projected at $17.43 billion, up from $16.39 billion a year ago [6] - 'HSAs Accounts' are likely to reach 10.21 million, compared to 9.51 million in the previous year [6] Stock Performance - Over the past month, HealthEquity shares have returned +11.2%, outperforming the Zacks S&P 500 composite's +0.4% change [7] - Based on its Zacks Rank 3 (Hold), HQY is expected to perform in line with the overall market in the upcoming period [7]

Core Viewpoint - Westport Innovations (WPRT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The upgrade for Westport suggests an improvement in the company's underlying business, which should encourage investors to drive the stock price higher [5]. - For the fiscal year ending December 2025, Westport is expected to earn -$2.82 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 14.6% over the past three months, indicating positive sentiment among analysts [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [7]. - The upgrade to Zacks Rank 2 places Westport in the top 20% of Zacks-covered stocks, suggesting it has a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Orion Energy Systems, Inc. (OESX) has shown a significant price increase of 41.2% over the past four weeks, with a mean price target of $17.83 indicating a potential upside of 26.4% from the current price of $14.11 [1] Price Targets and Analyst Consensus - The average price target for OESX ranges from a low of $15.00 to a high of $20.00, with a standard deviation of $2.57, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a 6.3% increase, while the highest suggests a 41.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about OESX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 57.1%, with two estimates moving higher and no negative revisions [12] - OESX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them for investment decisions may not be prudent due to potential biases in analyst estimates [3][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Group 1 - Keros Therapeutics, Inc. (KROS) shares have increased by 14.1% over the past four weeks, closing at $17.32, with a mean price target of $23.25 indicating a potential upside of 34.2% [1] - The average price targets from analysts range from a low of $16.00 to a high of $35.00, with a standard deviation of $5.95, suggesting variability in estimates [2] - Analysts show strong agreement on KROS's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for KROS's current year earnings has increased by 484% over the past month, with six estimates revised upward and no negative revisions [12] - KROS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Core Viewpoint - Immuneering Corporation (IMRX) has seen a 14.6% increase in share price over the past four weeks, closing at $7.44, with analysts suggesting a potential upside of 126.2% based on a mean price target of $16.83 [1][11]. Price Targets and Analyst Consensus - The average price target for IMRX is based on six short-term estimates, ranging from a low of $11.00 to a high of $30.00, with a standard deviation of $7.19, indicating variability in analyst predictions [2]. - The lowest estimate suggests a 47.9% increase from the current price, while the highest estimate indicates a potential upside of 303.2% [2]. - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 13.4%, with three estimates moving higher and no negative revisions [12]. - IMRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Core Viewpoint - Life Time Group Holdings, Inc. (LTH) shows significant upside potential with a mean price target of $40.36, indicating a 46.6% increase from the current price of $27.54 [1] Price Targets - The average of 11 short-term price targets ranges from a low of $33.00 to a high of $48.00, with a standard deviation of $4.59, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 19.8% increase, while the highest suggests a 74.3% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Earnings Estimates - Analysts are optimistic about LTH's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [4][11] - Over the last 30 days, three earnings estimates have been revised higher, leading to a 4.5% increase in the Zacks Consensus Estimate [12] Zacks Rank - LTH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of LTH's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - OrthoPediatrics (KIDS) shares have increased by 12.9% in the past four weeks, closing at $19.09, with a potential upside of 26.5% based on Wall Street analysts' mean price target of $24.14 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $5.01, indicating variability among analysts [2] - The lowest estimate is $19.00, suggesting a slight decline of 0.5%, while the highest estimate is $34.00, indicating a potential surge of 78.1% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding KIDS' ability to report better earnings than previously predicted supports the potential upside [4] - A positive trend in earnings estimate revisions has been shown to correlate with stock price movements, enhancing the outlook for KIDS [11] - Over the last 30 days, one earnings estimate has increased, leading to a 4.3% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - KIDS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - While consensus price targets may not be reliable for predicting gains, they can provide a directional guide for potential price movements [14]

Core Viewpoint - Amicus Therapeutics (FOLD) has shown a significant price increase of 11.4% over the past four weeks, with a mean price target of $15.64 indicating a potential upside of 58.5% from the current price of $9.87 [1] Price Targets and Analyst Consensus - The average price target consists of 11 estimates ranging from a low of $11.00 to a high of $21.00, with a standard deviation of $3.29, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 11.5% increase, while the highest suggests an upside of 112.8% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding FOLD's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, three estimates have increased, leading to a Zacks Consensus Estimate rise of 263.6% [12] - FOLD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8]

Core Viewpoint - Shares of Compass Therapeutics, Inc. (CMPX) have increased by 22.2% in the past four weeks, closing at $5.01, with a mean price target of $12.73 indicating a potential upside of 154.1% [1] Price Targets and Analyst Consensus - The average of 11 short-term price targets ranges from a low of $7.00 to a high of $30.00, with a standard deviation of $7.4, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 39.7% increase from the current price, while the highest suggests a 498.8% upside [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Potential Upside - Analysts have shown increasing optimism about CMPX's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 18.7% over the past month, with seven estimates increasing and no negative revisions [12] - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to the questionable ability of analysts to set accurate targets [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - Despite the skepticism surrounding price targets, the direction they imply can serve as a useful guide for further research [10][14]